ArticleOncology letters2019
Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- ComprehensiveOncology reports · 2025Review
- Tight junctional protein family, Claudins in cancer and cancer metastasis.Frontiers in oncology · 2025Review
- SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.Journal for immunotherapy of cancer · 2024Article
- Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2024Review
- Expression patterns of claudins in cancer.Heliyon · 2023Review
- Binding of YY1/CREB to an Enhancer Region Triggers Claudin 6 Expression inInternational journal of molecular sciences · 2023Article
- The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.Journal of translational medicine · 2023Article
- CLDN6 Suppresses Migration and Invasion of MCF-7 and SKBR-3 Breast Cancer Cells by Blocking the SMAD/Snail/MMP-2/9 Axis.Bulletin of experimental biology and medicine · 2023Article
- Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.BMC urology · 2023Article
- The role of claudin-6 in chromophobe renal cell carcinoma.Histology and histopathology · 2023Article
- Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.Urologia internationalis · 2023Article
- Anticancer activity ofIranian journal of basic medical sciences · 2023Article
- Chromosomally Unstable Gastric Cancers Overexpressing Claudin-6 Disclose Cross-Talk between HNF1A and HNF4A, and Upregulated Cholesterol Metabolism.International journal of molecular sciences · 2022Article
- Application of C-Terminal Clostridium Perfringens Enterotoxin in Treatment of Brain Metastasis from Breast Cancer.Cancers · 2022Review
- Claudins and Gastric Cancer: An Overview.Cancers · 2022Review
- The role and mechanism of claudins in cancer.Frontiers in oncology · 2022Review
- An Unsupervised Deep Learning-Based Model Using Multiomics Data to Predict Prognosis of Patients with Stomach Adenocarcinoma.Computational and mathematical methods in medicine · 2022Article
- Prediction of Gastric Cancer-Related Genes Based on the Graph Transformer Network.Frontiers in oncology · 2022Article
- Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial.Frontiers in surgery · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of claudin-6 (CLDN6) in the tissues of gastric cancer patients and its association with clinical pathology and prognosis were investigated. A retrospective analysis was performed on 213 gastric cancer patients diagnosed and surgically treated in the Central Hospital of Zibo from January 2010 to January 2013. Cancer and normal adjacent tissues were obtained from the patients to detect the expression level of CLDN6 using reverse transcription-quantitative PCR (RT-qPCR). The association between the expression level of CLDN6 and the clinical and pathological features, as well as the prognosis of gastric cancer patients was analyzed. The expression level of CLDN6 was significantly lower in gastric cancer tissues than that in adjacent tissues (t=23.350, P<0.001). The expression level of CLDN6 was associated with age, lymph node metastasis, pathological staging, and distant metastasis (P<0.05). In this study, patients were separated into CLDN6 high-expression group (≥1.42) with 107 patients and CLDN6 low-expression group (<1.42) with 106 patients, with the median expression level of CLDN6 as the boundary. The 1-, 2- and 3-year survival rates of patients in the CLDN6 low-expression group were 80.19, 60.38 and 48.11%, respectively, and those in the CLDN6 high-expression group were 87.85, 73.83 and 66.36%, respectively. The survival rate was significantly better in the CLDN6 high-expression group than that in the CLDN6 low-expression group (P=0.009). In conclusion, the expression level of CLDN6 is low in the cancer tissues of gastric cancer patients, and associated with age, lymph node metastasis, pathological staging and distant metastasis. CLDN6 low expression has a certain negative impact on the prognosis of patients, and therefore, shows potential as an important indicator for the prognosis of gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.